The use of international arbitration has augmented over the
years to include a wide range of sectors. While the majority of
financial disputes still transpire in court, some of them are
submitted to arbitration.
Life sciences giants often move out of their domestic markets in
search of better growth opportunities in developed and emerging
markets. Many of those developed and emerging markets already have
their own pharma companies with significant annual revenues. For
example, Mexico, Brazil, Russia, MEA REGION, India, Indonesia and
South Africa all have pharmaceutical companies with revenue of USD
1 billion. The complex supply and distribution chains engaged by
many pharma companies often extent multiple jurisdictions.
Arbitration is well-suited for the settlement of disputes arising
out of these types of complex, multi-jurisdictional agreements.